Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wodnar-Filipowicz, A.
Right arrow Articles by Nissen, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wodnar-Filipowicz, A.
Right arrow Articles by Nissen, C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Levels of soluble stem cell factor in serum of patients with aplastic anemia

A Wodnar-Filipowicz, S Yancik, Y Moser, V dalle Carbonare, A Gratwohl, A Tichelli, B Speck and C Nissen

Department of Research, University Hospital, Basel, Switzerland.

Aplastic anemia (AA) is a rare bone marrow (BM) disorder characterized by an unexplained failure of hematopoietic precursors to proliferate. In vitro growth of AA BM cells can be improved by the addition of the hematopoietic growth factor SCF (stem cell factor), which suggests that deficiency of SCF may be one of the underlying causes of the disease. In this study, we measured the concentration of SCF in sera of patients with severe AA. One hundred twenty-eight serum samples from 32 patients, at diagnosis and following therapy, were analyzed. Before treatment, SCF levels varied between 0.33 and 6.1 ng/mL; no correlation between hematopoietic function and SCF serum levels was apparent. Therapy with antilymphocyte globulin (ALG) or bone marrow transplantation (BMT) did not result in a recognizable pattern of changes in SCF levels. However, serum concentration of SCF in many patients with AA was at the low range of control serum levels determined in healthy blood donors. Of 128 AA serum samples tested before and after therapy, 107 were below the mean normal value of 3.3 ng/mL, including 26 samples below the minimum normal value of 1.3 ng/mL, as estimated in 267 controls. We also found that SCF levels in peripheral blood serum correlate well with factor concentrations in the BM plasma. Clinical observations suggest that higher SCF serum levels are often associated with a better clinical status of the patients in terms of survival and transfusion requirements. The data indicate that a deficient production of soluble SCF may contribute to AA in some patients; thus, suggesting a potential therapeutic benefit of SCF in this disorder.

Volume 81, Issue 12, pp. 3259-3264, 06/15/1993
Copyright © 1993 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
P. W. Zandstra, D. A. Lauffenburger, and C. J. Eaves
A ligand-receptor signaling threshold model of stem cell differentiation control: a biologically conserved mechanism applicable to hematopoiesis
Blood, August 15, 2000; 96(4): 1215 - 1222.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Akin, L. B. Schwartz, T. Kitoh, H. Obayashi, A. S. Worobec, L. M. Scott, and D. D. Metcalfe
Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology
Blood, August 15, 2000; 96(4): 1267 - 1273.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Tagaya, T. Kunisada, H. Yamazaki, T. Yamane, T. Tokuhisa, E. F. Wagner, T. Sudo, L. D. Shultz, and S.-I. Hayashi
Intramedullary and extramedullary B lymphopoiesis in osteopetrotic mice
Blood, June 1, 2000; 95(11): 3363 - 3370.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Chklovskaia, W. Jansen, C. Nissen, S. D. Lyman, C. Rahner, L. Landmann, and A. Wodnar-Filipowicz
Mechanism of flt3 Ligand Expression in Bone Marrow Failure: Translocation From Intracellular Stores to the Surface of T Lymphocytes After Chemotherapy-Induced Suppression of Hematopoiesis
Blood, April 15, 1999; 93(8): 2595 - 2604.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Podesta, G. Piaggio, F. Frassoni, A. Pitto, P. Zikos, M. Sessarego, M. Abate, M. Teresa Van Lint, G. Berisso, and A. Bacigalupo
The Assessment of the Hematopoietic Reservoir After Immunosuppressive Therapy or Bone Marrow Transplantation in Severe Aplastic Anemia
Blood, March 15, 1998; 91(6): 1959 - 1965.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. C. Broudy
Stem Cell Factor and Hematopoiesis
Blood, August 15, 1997; 90(4): 1345 - 1364.
[Full Text] [PDF]


Home page
NEJMHome page
N. S. Young and J. Maciejewski
The Pathophysiology of Acquired Aplastic Anemia
N. Engl. J. Med., May 8, 1997; 336(19): 1365 - 1372.
[Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1993 by American Society of Hematology         Online ISSN: 1528-0020